In vitro priming of tumor-antigen specific T-cells

This test will verify whether the fusion vaccine possesses the properties of both parental cell types for inducing primary CD8+ T-cell responses (data will become available).
Detection of circulating tumour-specific CD8+ T-cells.

BruCells has met with the Dutch MEB for a Scientific Advice Meeting on January 10, 2008 in The Hague.
The Dutch authorities consider that the proposed in-vitro pre-clinical tests are adequate to check the pharmacodynamic activity of the fusion vaccines and that no animal model tests would be necessary.

created over 15 years ago (24 February 2010)    last modified over 11 years ago (13 May 2013)   [ RDF ]   [ RelFinder ]